Alpha Tau Medical Ltd. — Form 6-K Summary
Reporting period: Form 6-K furnished on November 22, 2022, covering the month of November 2022 and referencing the company’s third-quarter 2022 financial results and corporate update. Alpha Tau Medical Ltd. is an Israeli foreign private issuer listed on Nasdaq under “DRTS.”
Financial metrics
The filing cover sheet does not include the underlying press release or its financial statements. Accordingly, the filing text provided does not state clear values for revenue, net income or loss, cash flow, margins, debt, cash and equivalents, liquidity, operating expenses, or other financial metrics.
The consolidated balance sheets and consolidated statements of operations contained in Exhibit 99.1 were incorporated by reference into the company’s Form S-8 registration statement. The referenced financial statements are not included in the provided text.
Material changes versus the prior comparable period
The filing indicates that the company issued a press release titled “Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update,” but the provided filing text does not describe the year-over-year or sequential changes in financial results, operating activity, clinical development, or corporate milestones.
Guidance, outlook, risks, and unusual items
No guidance, outlook, risk factors, contingencies, or unusual items are described in the provided filing text. Any corporate update, clinical developments, regulatory matters, or financing information would be contained in Exhibit 99.1, which is referenced but not reproduced.
Investor verification checklist
- Obtain and review Exhibit 99.1, the November 22, 2022 press release.
- Verify third-quarter 2022 revenue, operating expenses, net loss, cash burn, and cash balance.
- Assess liquidity, debt obligations, and expected funding needs from the consolidated balance sheets.
- Compare third-quarter 2022 results with the prior-year and immediately preceding comparable periods.
- Review the corporate update for clinical, regulatory, operational, financing, and guidance-related developments.